Beam Therapeutics, Inc. (BEAM)
28.34
-1.42
(-4.77%)
USD |
NASDAQ |
Aug 24, 16:00
28.46
+0.12
(+0.42%)
After-Hours: 19:54
Beam Therapeutics Debt to Equity Ratio : 0.2317 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2317 |
| March 31, 2026 | 0.2154 |
| December 31, 2025 | 0.1245 |
| September 30, 2025 | 0.1567 |
| June 30, 2025 | 0.1479 |
| March 31, 2025 | 0.1408 |
| December 31, 2024 | 0.2201 |
| September 30, 2024 | 0.2048 |
| June 30, 2024 | 0.1935 |
| March 31, 2024 | 0.184 |
| December 31, 2023 | 0.1765 |
| September 30, 2023 | 0.2233 |
| June 30, 2023 | 0.2182 |
| March 31, 2023 | 0.2349 |
| December 31, 2022 | 0.2482 |
| September 30, 2022 | 0.2498 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.222 |
| March 31, 2022 | 0.1811 |
| December 31, 2021 | 0.1786 |
| September 30, 2021 | 0.1703 |
| June 30, 2021 | 0.26 |
| March 31, 2021 | 0.3234 |
| December 31, 2020 | 0.4384 |
| September 30, 2020 | 0.1716 |
| June 30, 2020 | 0.1568 |
| March 31, 2020 | 0.1368 |
| December 31, 2019 | 0.3095 |
| September 30, 2019 | 0.2133 |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Twist Bioscience Corp. | 0.21 |
| Prime Medicine, Inc. | 2.825 |
| Intellia Therapeutics, Inc. | 0.1009 |
| Sana Biotechnology, Inc. | 0.4771 |
| Cartesian Therapeutics, Inc. | -0.5099 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.386B |
| Total Liabilities (Quarterly) | 318.91M |
| Shareholders Equity (Quarterly) | 1.067B |
| Current Ratio | 14.57 |
| Net Debt Paydown Yield | -0.50% |